{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:11:11Z","timestamp":1772575871959,"version":"3.50.1"},"reference-count":160,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.blre.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T10:16:47Z","timestamp":1501928207000},"page":"426-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pathways towards indolent B-cell lymphoma \u2014 Etiology and therapeutic strategies"],"prefix":"10.1016","volume":"31","author":[{"given":"Michiel","family":"van den Brand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Scheijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-8948","authenticated-orcid":false,"given":"Corine J.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Han JM","family":"van Krieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia J.T.A.","family":"Groenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","article-title":"Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma","volume":"8","author":"Zullo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0010","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jcp.47.5.436","article-title":"Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas","volume":"47","author":"Eidt","year":"1994","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P","article-title":"Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients","volume":"79","author":"Nakamura","year":"1997","journal-title":"Cancer"},{"issue":"8776","key":"10.1016\/j.blre.2017.08.002_bb0020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0140-6736(91)92035-Z","article-title":"Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma","volume":"338","author":"Wotherspoon","year":"1991","journal-title":"Lancet"},{"issue":"8871","key":"10.1016\/j.blre.2017.08.002_bb0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0140-6736(93)91409-F","article-title":"Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori","volume":"342","author":"Wotherspoon","year":"1993","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2013.09.004","article-title":"Marginal zone lymphomas and infectious agents","volume":"23","author":"Ferreri","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.beha.2004.08.003","article-title":"Update on MALT lymphomas","volume":"18","author":"Isaacson","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0040","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/leu.2010.118","article-title":"Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism","volume":"24","author":"Hamoudi","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.2005.081117","article-title":"Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H. pylori eradication","volume":"55","author":"Ye","year":"2006","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.blre.2017.08.002_bb0050","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2012-06-438424","article-title":"Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial","volume":"120","author":"Ferreri","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2017.08.002_bb0055","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2012-01-404194","article-title":"Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive gastric diffuse large B-cell lymphomas","volume":"119","author":"Kuo","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ajh.20962","article-title":"Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea","volume":"82","author":"Yoo","year":"2007","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0065","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2005-06-2332","article-title":"Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci","volume":"107","author":"Rosado","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0075","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2005.09.012","article-title":"Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience","volume":"30","author":"Vargas","year":"2006","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10428190601132105","article-title":"Lack of an association between Chlamydia psittaci and ocular adnexal lymphoma","volume":"48","author":"Zhang","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.blre.2017.08.002_bb0085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.leukres.2005.12.003","article-title":"No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands","volume":"30","author":"Mulder","year":"2006","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2005.05943.x","article-title":"Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients","volume":"132","author":"Daibata","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djj079","article-title":"Re: evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"98","author":"de Cremoux","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.1984","article-title":"Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions","volume":"209","author":"Chanudet","year":"2006","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0105","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.leukres.2007.10.013","article-title":"Chlamydia psittaci in MALT lymphomas of ocular adnexals: the Austrian experience","volume":"32","author":"Aigelsreiter","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1532\/IJH97.06065","article-title":"Absence of chlamydial infection in Japanese patients with ocular adnexal lymphoma of mucosa-associated lymphoid tissue","volume":"85","author":"Yakushijin","year":"2007","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0115","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2017.08.002_bb0120","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.blre.2017.08.002_bb0125","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","article-title":"Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma","volume":"24","author":"Cerroni","year":"1997","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0135","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","article-title":"Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland","volume":"24","author":"Goodlad","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0140","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2559.2000.01003.x","article-title":"Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin","volume":"37","author":"Goodlad","year":"2000","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"350","author":"Lecuit","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0150","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.dld.2012.03.020","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"44","author":"Mesnard","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0155","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.12703","article-title":"Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe","volume":"164","author":"Adam","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0160","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2006-08-044008","article-title":"Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia","volume":"109","author":"Landgren","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2017.08.002_bb0165","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/modpathol.3880424","article-title":"Detection of Toxoplasma gondii DNA in primary intraocular B-cell lymphoma","volume":"14","author":"Shen","year":"2001","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.20205","article-title":"B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review","volume":"111","author":"Negri","year":"2004","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0175","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2003.09.025","article-title":"Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis","volume":"125","author":"Gisbert","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0180","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/asheducation-2014.1.590","article-title":"Hepatitis C virus-associated B-cell non-Hodgkin lymphomas","volume":"2014","author":"Vannata","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2017.08.002_bb0190","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2004-05-1711","article-title":"Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?","volume":"105","author":"Saadoun","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0205","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","article-title":"Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas","volume":"145","author":"Mazzaro","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2017.08.002_bb0215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4254\/wjh.v3.i11.278","article-title":"Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma","volume":"3","author":"Pellicelli","year":"2011","journal-title":"World J Hepatol"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ajh.23889","article-title":"Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study","volume":"90","author":"Michot","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/2040620715623924","article-title":"Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?","volume":"7","author":"Vannata","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14309\/crj.2015.104","article-title":"Lymphoma remission by interferon-free HCV eradication without chemotherapy","volume":"3","author":"Lim","year":"2015","journal-title":"ACG Case Rep J"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0235","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2014.09.031","article-title":"Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3\/NS4A inhibitor-based treatment. A case report","volume":"62","author":"Rossotti","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0240","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.semcancer.2013.07.006","article-title":"Antigen selection in B-cell lymphomas\u2014tracing the evidence","volume":"23","author":"Sutton","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"19","key":"10.1016\/j.blre.2017.08.002_bb0245","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0250","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"issue":"11\u221212","key":"10.1016\/j.blre.2017.08.002_bb0255","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2119\/2008-00102.Catera","article-title":"Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation","volume":"14","author":"Catera","year":"2008","journal-title":"Mol Med"},{"issue":"13","key":"10.1016\/j.blre.2017.08.002_bb0260","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","article-title":"Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA","volume":"112","author":"Chu","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0265","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1172\/JCI24387","article-title":"Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity","volume":"115","author":"Herve","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0270","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","article-title":"A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies","volume":"111","author":"Lanemo Myhrinder","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2017.08.002_bb0275","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2011-03-341651","article-title":"Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity","volume":"118","author":"Warsame","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.08.002_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V108.11.25.25","article-title":"B-cell chronic lymphocytic leukemia (B-CLL) cells express antibodies reactive with antigenic epitopes expressed on the surface of common bacteria","volume":"108","author":"Hatzi","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0285","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/leu.2008.379","article-title":"Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors","volume":"23","author":"Kostareli","year":"2009","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.blre.2017.08.002_bb0290","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0295","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstrom Smedby","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0300","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.20050068","article-title":"Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity","volume":"201","author":"Bende","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0305","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/1529-0131(200004)43:4<908::AID-ANR24>3.0.CO;2-K","article-title":"Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells","volume":"43","author":"Martin","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0310","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.13192","article-title":"Sjogren Syndrome-associated lymphomas: an update on pathogenesis and management","volume":"168","author":"Nocturne","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0315","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/leu.2011.276","article-title":"Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation","volume":"26","author":"Dagklis","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0320","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.V85.9.2528.bloodjournal8592528","article-title":"Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals","volume":"85","author":"Limpens","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0325","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2013.085548","article-title":"Nature and importance of follicular lymphoma precursors","volume":"99","author":"Mamessier","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0330","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2013.307","article-title":"Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2017.08.002_bb0335","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2011-05-355255","article-title":"Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma","volume":"118","author":"Jegalian","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0340","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2017.08.002_bb0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2013.08.003","article-title":"Monoclonal B cell lymphocytosis and \u201cin situ\u201d lymphoma","volume":"24","author":"Karube","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"20","key":"10.1016\/j.blre.2017.08.002_bb0350","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0355","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminoncol.2016.02.013","article-title":"What does it mean I have a monoclonal B-cell lymphocytosis?: recent insights and new challenges","volume":"43","author":"Scarfo","year":"2016","journal-title":"Semin Oncol"},{"issue":"25","key":"10.1016\/j.blre.2017.08.002_bb0360","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1182\/blood-2011-05-357251","article-title":"General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL","volume":"118","author":"Fazi","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2017.08.002_bb0365","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1158\/1078-0432.CCR-13-0622","article-title":"Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features","volume":"19","author":"Morabito","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0370","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2015.134510","article-title":"Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond","volume":"101","author":"Rosenquist","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0375","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/bjc.2016.78","article-title":"The clinical implications of gene mutations in chronic lymphocytic leukaemia","volume":"114","author":"Rossi","year":"2016","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.blre.2017.08.002_bb0380","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0385","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2017.08.002_bb0390","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4706","key":"10.1016\/j.blre.2017.08.002_bb0395","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.blre.2017.08.002_bb0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","volume":"155","author":"Scarfo","year":"2013","journal-title":"Immunol Lett"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0405","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.V90.3.1168","article-title":"BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma","volume":"90","author":"Monni","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0410","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"39","key":"10.1016\/j.blre.2017.08.002_bb0415","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"10.1016\/j.blre.2017.08.002_bb0420","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2011.41.0852","article-title":"Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial","volume":"30","author":"Skowronska","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2017.08.002_bb0425","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2017.08.002_bb0430","doi-asserted-by":"crossref","first-page":"19012","DOI":"10.1074\/jbc.M009984200","article-title":"Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway","volume":"276","author":"Lucas","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0435","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0092-8674(00)80957-5","article-title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types","volume":"96","author":"Willis","year":"1999","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0440","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/8767","article-title":"Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)","volume":"22","author":"Zhang","year":"1999","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.blre.2017.08.002_bb0445","doi-asserted-by":"crossref","first-page":"9962","DOI":"10.1074\/jbc.274.15.9962","article-title":"Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase","volume":"274","author":"Thome","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0450","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/leu.2009.234","article-title":"A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma","volume":"24","author":"Chanudet","year":"2010","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.blre.2017.08.002_bb0455","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2017.08.002_bb0460","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-\u03baB pathway genes in splenic marginal zone lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0465","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0470","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Martinez","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0475","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0480","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.blre.2017.08.002_bb0485","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"7354","key":"10.1016\/j.blre.2017.08.002_bb0490","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.blre.2017.08.002_bb0495","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0500","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.blre.2017.08.002_bb0505","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0510","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/leu.2011.266","article-title":"High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis","volume":"26","author":"Launay","year":"2012","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.blre.2017.08.002_bb0515","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1073\/pnas.0902115106","article-title":"Unconventional ligand activation of herpesvirus entry mediator signals cell survival","volume":"106","author":"Cheung","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.blre.2017.08.002_bb0520","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.blre.2017.08.002_bb0525","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1038\/sj.leu.2403175","article-title":"Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity","volume":"17","author":"Costello","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0530","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"29","key":"10.1016\/j.blre.2017.08.002_bb0535","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0540","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2017.08.002_bb0545","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0550","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0555","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0560","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2017.08.002_bb0565","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2017.08.002_bb0570","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0575","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0580","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2017.08.002_bb0585","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2017.08.002_bb0590","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2017.08.002_bb0595","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0600","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ajhg.2012.08.006","article-title":"A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency","volume":"91","author":"Zhou","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.blre.2017.08.002_bb0605","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2017.08.002_bb0610","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2017.08.002_bb0615","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.V126.23.1543.1543","article-title":"Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)","volume":"126","author":"Martin","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2017.08.002_bb0620","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2017.08.002_bb0625","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0635","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev"},{"issue":"18","key":"10.1016\/j.blre.2017.08.002_bb0640","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0645","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2017.08.002_bb0650","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1517\/14656566.2014.965142","article-title":"Bortezomib for the treatment of non-Hodgkin's lymphoma","volume":"15","author":"Bose","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0655","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol Med"},{"issue":"5134","key":"10.1016\/j.blre.2017.08.002_bb0660","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.8235596","article-title":"Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma","volume":"262","author":"Ye","year":"1993","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0665","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","article-title":"Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component","volume":"165","author":"Katzenberger","year":"2004","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.blre.2017.08.002_bb0670","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0675","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","article-title":"A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma","volume":"12","author":"Saito","year":"2007","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.blre.2017.08.002_bb0680","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ni.2688","article-title":"MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma","volume":"14","author":"Ying","year":"2013","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0685","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1084\/jem.20100204","article-title":"DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas","volume":"207","author":"Lai","year":"2010","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0690","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ccr.2009.12.050","article-title":"A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo","volume":"17","author":"Cerchietti","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0695","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.18632\/oncotarget.6513","article-title":"Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma","volume":"7","author":"Dupont","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0700","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/10428190801895345","article-title":"Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas","volume":"49","author":"Parekh","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2017.08.002_bb0705","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/ng1018","article-title":"Acetylation inactivates the transcriptional repressor BCL6","volume":"32","author":"Bereshchenko","year":"2002","journal-title":"Nat Genet"},{"issue":"16","key":"10.1016\/j.blre.2017.08.002_bb0710","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2013-08-355818","article-title":"Notch signaling: switching an oncogene to a tumor suppressor","volume":"123","author":"Lobry","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0715","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.semcancer.2013.04.002","article-title":"Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies","volume":"23","author":"Rossi","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0720","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/path.2789","article-title":"Notch signalling in T-cell lymphoblastic leukaemia\/lymphoma and other haematological malignancies","volume":"223","author":"Aster","year":"2011","journal-title":"J Pathol"},{"issue":"5694","key":"10.1016\/j.blre.2017.08.002_bb0725","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0730","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0735","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.blre.2017.08.002_bb0740","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/path.4428","article-title":"Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours","volume":"234","author":"Karube","year":"2014","journal-title":"J Pathol"},{"issue":"21","key":"10.1016\/j.blre.2017.08.002_bb0745","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"7360","key":"10.1016\/j.blre.2017.08.002_bb0750","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"7337","key":"10.1016\/j.blre.2017.08.002_bb0755","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2017.08.002_bb0760","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.blre.2017.08.002_bb0765","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3109\/10428194.2014.982638","article-title":"Tumor suppressors in follicular lymphoma","volume":"56","author":"Graham","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2017.08.002_bb0770","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2017.08.002_bb0775","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2017.08.002_bb0780","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/annonc\/mdw029","article-title":"Breakthrough therapies in B-cell non-Hodgkin lymphoma","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.blre.2017.08.002_bb0785","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.blre.2017.08.002_bb0790","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2017.08.002_bb0795","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2017.08.002_bb0800","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini","year":"2016","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16301163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16301163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T08:15:53Z","timestamp":1602663353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16301163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":160,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0268960X16301163"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2017.08.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathways towards indolent B-cell lymphoma \u2014 Etiology and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}